Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors toFVIII-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors toFVIII

Published:2018-06-14 Issue:4 Volume:24 Page:570-577
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Carpenter S. L.¹²³,Khair K.⁴⁵^ORCID,Gringeri A.⁶,Valentino L. A.⁷^ORCID

Affiliation:

1. Hematology/OncologyUniversity of Missouri Kansas City School of Medicine Kansas City MO USA

2. Kansas City Regional Hemophilia Treatment Center Kansas City MO USA

3. Children's Mercy Hospital Kansas City MO USA

4. Great Ormond Street Hospital London UK

5. London South Bank University London UK

6. Shire Vienna Austria

7. Shire Lexington MA USA

Funder

Pfizer

Baxter International

Novo Nordisk

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13534

Reference57 articles.

1. Factor VIII Products and Inhibitor Development in Severe Hemophilia A

2. European Study on Orthopaedic Status of haemophilia patients with inhibitors

3. Impact of inhibitors on hemophilia a mortality in the United States

4. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication;Blood Advances;2023-04-28

2. Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review;Orphanet Journal of Rare Diseases;2023-03-07

3. Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy;International Journal of Hematology;2022-05-03

4. Management of acquired hemophilia: Consensus recommendations for the United Arab Emirates practitioners;Journal of Applied Hematology;2022

5. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor;International Journal of Hematology;2021-02-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3